U.S. markets open in 16 minutes

Earnings Preview: ScanSource (SCSC) Q2 Earnings Expected to Decline

Zacks Equity Research

The market expects ScanSource (SCSC) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2019. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.

The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on February 4. On the other hand, if they miss, the stock may move lower.

While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.

Zacks Consensus Estimate

This technology products distributor is expected to post quarterly earnings of $0.82 per share in its upcoming report, which represents a year-over-year change of -17.2%.

Revenues are expected to be $908.25 million, down 13.2% from the year-ago quarter.

Estimate Revisions Trend

The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.

Price, Consensus and EPS Surprise

Earnings Whisper

Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for ScanSource?

For ScanSource, the Most Accurate Estimate is the same as the Zacks Consensus Estimate, suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate. This has resulted in an Earnings ESP of 0%.

On the other hand, the stock currently carries a Zacks Rank of #3.

So, this combination makes it difficult to conclusively predict that ScanSource will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?

Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that ScanSource would post earnings of $0.74 per share when it actually produced earnings of $0.72, delivering a surprise of -2.70%.

Over the last four quarters, the company has beaten consensus EPS estimates just once.

Bottom Line

An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

ScanSource doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
ScanSource, Inc. (SCSC) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.

  • Amazon to suspend delivery service competing with UPS, FedEx
    Business
    Reuters

    Amazon to suspend delivery service competing with UPS, FedEx

    The online retailer told customers that the service, Amazon Shipping, will be paused starting in June, according to the Wall Street Journal, which was first to report the change. Amazon is suspending the service because it needs people and capacity to handle a surge in its own customers’ orders, the Journal reported, citing sources. "We regularly look at a variety of factors across Amazon to make sure we're set up in the right way to best serve our customers," an Amazon spokesperson told Reuters in an email confirming the halt in service.

  • Saudi Crude Oil Armada Heads for U.S.
    Business
    Bloomberg

    Saudi Crude Oil Armada Heads for U.S.

    On the final day of March, the supertanker Newton, loaded with crude from Saudi Arabia, did something rarely seen in the world of oil trading: it abruptly diverted from its original destination, Egypt, setting sail for the U.S. Gulf Coast instead. The Newton is just part of a flood of Saudi crude that's headed for the U.S., with oil prices near the lowest levels in almost two decades. And it occurs as President Trump's administration considers tariffs on imports of oil from OPEC's largest producer.

  • China’s Streaming Platform iQIYI Retaliates Against Short Seller Report
    Business
    SmarterAnalyst

    China’s Streaming Platform iQIYI Retaliates Against Short Seller Report

    In its April 7 report, Wolfpack alleges that “IQ was committing fraud well before its IPO in 2018 and has continued to do so ever since. It estimates that IQ inflated its 2019 revenue by approximately RMB 8-13 billion, or 27%-44%, by overstating its user numbers by approximately 42%-60%. According to the report, IQ inflates its expenses, the prices it pays for content, other assets, and acquisitions to “burn off fake cash to hide the fraud from its auditor and investors.

  • Nvidia Reverses From Buy Zone
    Business
    Investor's Business Daily Video

    Nvidia Reverses From Buy Zone

    Nvidia jumped above a 275.50 cup-with-handle buy point at the open, but reversed lower. Looks like it'll try to hold 50-day line. Example of why it's good to wait 30/60 minutes after open to see how stock

  • Why Is Warren Buffett Ignoring the Coronavirus Market Dip?
    Business
    Worth

    Why Is Warren Buffett Ignoring the Coronavirus Market Dip?

    Investors are beginning to speculate what is Berkshire Hathaway CEO Warren Buffett going to buy. After all, it is Buffett who said “…be greedy only when others are fearful.” Market commentators turned bleaker every day, while the S&P 500 kept tumbling lower and lower, apart from brief periods of brutal volatility.

  • Billionaire Steven Cohen Picks up These 2 Stocks on the Dip
    Business
    TipRanks

    Billionaire Steven Cohen Picks up These 2 Stocks on the Dip

    The Point72 Chairman and CEO has earned a reputation as one of the most successful stock pickers, with his firm relying on a core hedge fund strategy that features stock market investments. Less frequently, Point72, which is based in Stamford, Connecticut, will make plays based on macro trends, placing global wagers on several asset classes at the same time. With Cohen earning an estimated $1.3 billion in 2019 after the firm's main hedge fund posted a 14.9% gain, it's no wonder market watchers follow his moves religiously.

  • 8 Dividends In Danger Of Being Cut
    Business
    Benzinga

    8 Dividends In Danger Of Being Cut

    The sell-off has driven dividend yields of a number of S&P 500 stocks to their highest levels in years. But as attractive as a double-digit dividend may seem on the surface, a dividend is only as good as the company paying it. The quickest way to assess the reliability of a dividend is to look at a company's payout ratio.

  • The Stock Market Has Become One Big Value Trap
    Business
    Bloomberg

    The Stock Market Has Become One Big Value Trap

    The problem is that many analysts have held off slashing their profit estimates, deciding to wait until they hear from company executives when the first-quarter earnings reporting season begins in a few weeks. Bloomberg News reports that Keith Parker, UBS AG's head of equity strategy, calculates that many firms hadn't updated their forecasts on individual company earnings for weeks. DEBT RULES THE WORLDGovernments globally are stepping up their debt issuance to raise cash to support their economies during the coronavirus pandemic.

  • Why one fund manager sees a wealth bubble putting the property and stock market at risk
    Business
    MarketWatch

    Why one fund manager sees a wealth bubble putting the property and stock market at risk

    He also discussed the current situation, and why European stocks have sold off more than U.S. equities even though he viewed the former as overvalued heading into the pandemic. More Europeans have died (so far), resulting in a higher fear factor on this side of the Atlantic, i.e. the impact on risk assets has been bigger,” said Jensen, adding that European markets also are less liquid. Before we come out on the other side of this crisis, more likely than not, the day will arrive when European equities begin to outperform U.S. equities, just like Chinese equities have outperformed equities from the rest of the world in recent weeks.

  • Business
    TheStreet.com

    The Average 401(k) Balance by Age

    Average 401(k) Balance by Age Here are the average 401(k) balance by age range as of the second quarter of 2019, according to data released by Fidelity Investments. Ages 20-29 The average 401(k) balance was $11,800 The median 401(k) balance was $4,300 The average contribution rate was 7% of compensation Ages 30-39 The average 401(k) balance was $42,400 The median 401(k) balance was $16,500 The average contribution rate was 7.8% of compensation Ages 40-49 The average 401(k) balance was $102,700 The median 401(k) balance was $36,000 The average contribution rate was 8.5% of compensation Ages 50-59 The average 401(k) balance was $174,100 The median 401(k) balance was $60,900 The average contrib...

  • Business
    Thomson Reuters StreetEvents

    Edited Transcript of DAL earnings conference call or presentation 10-Oct-19 2:00pm GMT

    Q3 2019 Delta Air Lines Inc Earnings Call

  • Family of a Walmart employee who died from COVID-19 files lawsuit
    Business
    WLS – Chicago

    Family of a Walmart employee who died from COVID-19 files lawsuit

    The family of a Walmart employee who died from COVID-19 is now suing the retailer.

  • Coronavirus crisis will leave 3 lasting scars, even if the economy recovers in fourth quarter, Pimco warns
    Business
    MarketWatch

    Coronavirus crisis will leave 3 lasting scars, even if the economy recovers in fourth quarter, Pimco warns

    The U.S. economy is in the midst of one of the deepest, most painful recessions the country has ever seen, but, as long as the pieces fall into place, it could also prove to be one of the shortest, according to a blog post from Joachim Fels, global economic adviser at Pimco. “Unlike previous recessions, usually caused by the interplay of economic and financial imbalances, interest rate hikes, or oil price spikes, the trigger of the present crisis is an exogenous shock,” he wrote. “We are seeing the first-ever recession by government decree — a necessary, temporary, partial shutdown of the economy aimed at preventing an even larger humanitarian crisis.”

  • Roku: Covid-19 to Impact Ad Revenue, Top Analyst Reduces Estimates
    Business
    SmarterAnalyst

    Roku: Covid-19 to Impact Ad Revenue, Top Analyst Reduces Estimates

    Following a massive run up in 2019, the stock shed 34% of its share price year-to-date. In mid-March, the stock was down as much as 55%, so if you sold there, you sold at the bottom. The severe drop is a tad surprising, as during these stay-at-home times, Roku should be one of the few names to reap the rewards of extra engagement on its platform.

  • Business
    Financial Times

    Luckin chief looks to limit scandal fallout

    The co-founder of China's would-be Starbucks rival Luckin Coffee, Lu Zhengyao, is seeking to distance himself from his network of other companies to help them weather the fallout from a scandal at the beverage group. Like Luckin Coffee, which attracted investment from foreign companies such as BlackRock, Mr Lu's other businesses — which include China Auto Rental, China's largest online car rental company, and Ucar, a chauffeur-car service — count overseas companies such as Warburg Pincus among their investors. In an interview with the Financial Times, company executives said Mr Lu would consider stepping down as chairman of China Auto Rental as one of a number of measures aimed at convincing investors of the group's independence from Luckin Coffee.

  • GenMark Sees 80% Q1 Revenue Boost on Covid-19 Tests
    Business
    SmarterAnalyst

    GenMark Sees 80% Q1 Revenue Boost on Covid-19 Tests

    GNMK announced that it received Emergency Use Authorization (EUA) for its ePlex SARS-CoV-2 test on March 19 and management noted that the COVID-19 test accounted for ~5% of ePlex revenue (~$1.7M) in 1Q20. With GNMK raising guidance by just the amount it beat in 1Q20, we believe that guidance leaves room for additional upside during 2020 and we reiterate our Buy rating” cheered Needham's Michael Matson on the news. Gross margin was also up significantly Y/Y which we suspect helped with GNMK's cash burn (which was already improving)” the analyst added.

  • Two Accounting Scandals in China in One Week Burn Investors
    Business
    Bloomberg

    Two Accounting Scandals in China in One Week Burn Investors

    TAL Education Group, a tutoring business whose success turned founder Zhang Bangxin into one of China's richest people, delivered the latest bombshell on Tuesday after saying a routine internal audit found an employee had inflated sales by forging contracts. Accounting firm Ernst & Young later said it discovered the fabrications when it audited the firm's financial statements. While China Inc. is no stranger to claims of financial irregularities -- particularly from short sellers who have targeted both TAL and Luckin in the recent past -- the fresh wave of revelations is once again putting the spotlight on corporate malpractice at U.S.-listed Chinese firms.

  • Is Apple Stock a Buy Right Now? This Is What You Need to Know
    Business
    SmarterAnalyst

    Is Apple Stock a Buy Right Now? This Is What You Need to Know

    Whether it is or not, according to one analyst, Apple (AAPL) is readying to unveil its new budget iPhone model, the iPhone 9/SE2, the follow up to the iPhone SE. Wedbush analyst Daniel Ives says that according to available supply chain information and various retail websites, the launch is weeks away. The unveiling - originally slated for March - was delayed on account of supply chain issues caused by the COVID-19 pandemic.

  • Why these stocks are worth holding as markets navigate a deadly pandemic
    Business
    MarketWatch

    Why these stocks are worth holding as markets navigate a deadly pandemic

    Steen Jakobsen, chief investment officer at Saxo Bank, notes how Denmark is among the first in Europe to announce a plan to reopen the economy. Luc Filip, head of private banking investments at Banque SYZ in Geneva, who provides our call of the day, adds to that, saying that investors need to remember that a “peak number of cases doesn't mean the economy will be reopened next week.” “There is a risk that the U.S., by postponing stronger measures, by hesitating, may have a larger outbreak and then a larger impact to the economy,” says Filip.

  • Stock market news live updates: Stock futures edge higher as investors eye pandemic developments
    Business
    Yahoo Finance

    Stock market news live updates: Stock futures edge higher as investors eye pandemic developments

    Stock futures rose Wednesday morning after a volatile session the prior day. Investors continued to monitor coronavirus developments, and early reports that the government was beginning to consider exit plans to restart businesses closed due to the outbreak. At the session highs on Tuesday, the S&P 500 rallied a total of more than 22% above its March 23 closing low, or 3.5% on the day, before ending the session slightly in the red.

  • Trump’s personal stake in the malaria-drug maker Sanofi could be as small as $99
    News
    MarketWatch

    Trump’s personal stake in the malaria-drug maker Sanofi could be as small as $99

    As President Donald Trump has persistently discussed the malaria drug hydroxychloroquine, critics have wondered about his motivation, given the drug's far-from-certain performance on the global stage as a treatment for coronavirus, and the Food and Drug Administration's refusal so far to approve it as a treatment for COVID-19. The New York Times says Trump has a “small personal stake” in Sanofi, the French drug manufacturer that produces the drug. The report doesn't say how small, but it notes that his three family trusts have investments in a Dodge & Cox mutual fund whose largest holding is Sanofi.

  • Luckin May Put Lasting Stain on China Inc. Listings
    Business
    Bloomberg

    Luckin May Put Lasting Stain on China Inc. Listings

    Shares in the company — whose $645 million IPO was the second largest in the U.S. by a Chinese firm in the last 12 months — have swooned 74%. Suddenly, Chinese companies' opaque numbers are dinner-table conversation again, with the scandal sending other listings from the nation into a tailspin and threatening to close off the overseas market for new issuers. After short sellers such as Muddy Waters, which bet against Luckin,  spotted Toronto-listed Sino-Forest's overstated timber assets in 2011, Chinese listings in the U.S. evaporated.

  • Is the Dow staging a genuine rebound? Here’s what experts think as the stock market attempts to shake the bearish grip of the coronavirus pandemic
    Business
    MarketWatch

    Is the Dow staging a genuine rebound? Here’s what experts think as the stock market attempts to shake the bearish grip of the coronavirus pandemic

    See: Vodka, saunas and resisting lockdown — the countries taking a different approach to the coronavirus “We are finally seeing U.S. COVID-19 new case numbers responding to social distancing — certainly in New York state but also elsewhere,” wrote analysts at BofA Global Research in a note. On top of that, central banks and governments across the globe are throwing out what amounts to trillions of dollars to help stanch the economic damage resulting from efforts to mitigate infections and treat those sickened by the illness derived from the novel strain of coronavirus.

  • Business
    TheStreet.com

    Teens' Love of All Things Apple Sparks Piper Sandler Price-Target Upgrade

    Teens' love affair with all things Apple , specifically the company's ubiquitous iPhone and its less pervasive smaller cousin, the Apple Watch, has prompted analysts at Piper Sandler to lift their one-year price target on the stock. Apple's price target was raised to $300 from $260 by Piper Sandler analyst Harsh Kumar, who cited a biannual survey his firm conducted of teenage consumers showing that the iPhone was the most popular smartphone among those polled, while the Apple Watch was the top smart watch. Kumar raised his price target on Apple to $300 from $260 and kept his overweight rating on the shares after the poll showed that 85% of the 5,200 teens surveyed by the firm have an iPhone, "the highest percentage we have seen in our survey."

  • Biotech vet Gilman's startup earns $190M-plus in Roche deal
    Business
    American City Business Journals

    Biotech vet Gilman's startup earns $190M-plus in Roche deal

    Michael Gilman's Waltham startup has found the one large, strategic partner it was looking for — but the COVID-19 outbreak almost tore them apart. Arrakis Therapeutics announced a widespread collaboration Wednesday with Swiss drug developer Roche, earning $190 million upfront and potentially billions in milestone payments. The pair first connected at the J.P. Morgan Healthcare Conference in 2017 and stayed in touch as Arrakis worked through the kinks of its sciences, sometimes hitting dead ends that required researchers to start over, Arrakis CEO Michael Gilman said.